Orphazyme CEO stays silent in run-up to creditor meeting
Anders Vadsholt, CFO and acting CEO of Orphazyme, doesn’t want to speak about any recent or past events that led to the ongoing in-court restructuring process while it takes place, he informs MedWatch in a text message.
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen
A line of defeats has been trailing biotech firm Orphazyme the past year, and the company recently announced that it is undergoing an in-court restructuring process.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme gets another annual report extension approved
For subscribers
